Biopharmaca BiofarmakaIn Vitro Antibacterial Activity of Panduratin A against Enterococci Clinical Isolates


In Vitro Antibacterial Activity of Panduratin A against Enterococci Clinical Isolates

Please use this identifier to cite or link to this item

In Vitro Antibacterial Activity of Panduratin A against Enterococci Clinical Isolates

Authors  Yaya Rukayadi1,2, Sunghwa Han3, Dongeun Yong4 and Jae-Kwan Hwang1,*



1Department of Biotechnology, Yonsei University;
2 Biopharmaca Research Center and Research Center for Biotechnology and Bioresources, Bogor Agricultural University; Bogor 16151, Indonesia.
3Department of Biomaterials Science and Engineering, Yonsei University;
4Department of Laboratory Medicine & Research Institute of Bacterial Resistance, Yonsei University; Seoul 120–749, Korea
*Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Issue Date : September 2010
Biological and Pharmaceutical Bulletin
© 2010 Pharmaceutical Society of Japan
Series / Report No :
ISSN: 0918-6158
Physical Description :
2010 Vol. 33No. 9 p 1489—1493
Language : en



Panduratin A, a natural chalcone compound isolated from the rhizome of fingerroot (Boesenbergia rotunda (L.) MANSF. A). The antibacterial activity of panduratin A against clinical enterococci isolates was compared in terms of minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) to those of commonly used antimicrobials, according to the CLSI guidelines. Time–kill curves were constructed to assess the concentration between MIC and bactericidal activity of panduratin A at concentrations ranging from 0XMIC to 4XMIC. The activity of panduratin A against biofilm-producing enterococcal strains was also evaluated. The growth of all clinical enterococci isolates (n=23) were inhibited by panduratin A at a concentration of 2 μg/ml. Panduratin A was able to kill all clinical enterococci isolates with a MBC of 8 μg/ml. The time–kill curves demonstrated that the bactericidal endpoint for clinical enterococci was reached after 30 min of incubation at a panduratin A concentration of 4XMIC. The growth of biofilm-producing enterococcal strains can be inhibited and eradicated by panduratin A at concentrations of ≤4 μg/ml and ≤16 μg/ml, respectively. The antibacterial activity of panduratin A against all clinical enterococci isolates was generally more potent than commonly used antimicrobials. Panduratin A has stronger activity against biofilm-producing enterococcal strains than daptomycin and linezolid. Panduratin A is an antimicrobial agent with high in vitro activity against clinical enterococci, including organisms resistant to other antimicrobials.

Source url




Anti-Bacterial Agents/chemistry Anti-Bacterial Agents/pharmacology*
Enterococcus faecalis/drug effects*
Enterococcus faecalis/isolation & purification*
Enterococcus faecium/drug effects*
Enterococcus faecium/isolation & purification*
Microbial Sensitivity Tests/methods

Keywords : antibacterial activity, enterococci, panduratin A
How to cite this article  :


Rukayadi, Y., S.Han, D. Yong & JK Hwang. 2010. In Vitro Antibacterial Activity of Panduratin A against Enterococci Clinical Isolates. Biol. Pharm. Bull, 33(9): 1489—1493.



Download Fulltext.


Back to BRC Journal.....

TropBRC SosMed

facebookgoogle plustwitter

BRC Site Statistics

  • Unique Visits Today1
  • Unique Visits Yesterday1
  • Visits This Week1
  • Visits Previous Week1